Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine

Bouzeman, Abdeslam; Traullé, Sarah; Messali, A.; Extramiana, Fabrice; Denjoy, Isabelle; Narayanan, Kumar; Marijon, Éloi; Hermida, Jean‐Sylvain; Leenhardt, Antoine

doi:10.1093/europace/eut279

Cited by 38 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…130 Of these, 34 (77%) were no longer inducible while treated with 600 mg/day hydroquinidine (HQ) for 6.2 ± 3 years. Among the 10 other patients (22%), who remained inducible and received ICD (Group PVS+), none received appropriate therapy during a mean follow-up of 7.7 ± 2 years.…”

Section: Introductionmentioning

confidence: 99%

J-wave syndromes: Brugada and early repolarization syndromes

2015

View full text Add to dashboard Cite

A prominent J wave is encountered in a number of life-threatening cardiac arrhythmia syndromes, including the Brugada (BrS) and early repolarization (ERS) syndromes. BrS and ERS differ with respect to the magnitude and lead location of abnormal J waves and are thought to represent a continuous spectrum of phenotypic expression termed J wave syndromes. Despite two decades of intensive research, risk stratification and the approach to therapy of these two inherited cardiac arrhythmia syndromes are still undergoing rapid evolution. Our objective in this review is to provide an integrated synopsis of the clinical characteristics, risk stratifiers, as well as the molecular, ionic, cellular and genetic mechanisms underlying these two fascinating syndromes that have captured the interest and attention of the cardiology community in recent years.

show abstract

Section: Introductionmentioning

confidence: 99%

J-wave syndromes: Brugada and early repolarization syndromes

2015

View full text Add to dashboard Cite

show abstract

“…A second PVS was performed in patients with therapeutic level of the drug and if VF was non-inducible, the drug was continued. In other cases, such as when VF was still inducible during PVS, and additional symptoms were present, an ICD was implanted [47]. Current ESC guidelines recommend quinidine in patients who have an indication for ICD implantation, but do not agree to such treatment, those who could benefit from an ICD but have a contraindication for such therapy, and in patients who require treatment due to supraventricular arrhythmias (class IIa indication) [18].…”

Section: Pharmacotherapymentioning

confidence: 99%

Brugada syndrome: new concepts and algorithms in management (RCD code: V 1A.1)

Matusik

Rydlewska

Pudło

et al. 2018

Journal of Rare Cardiovascular Diseases

View full text Add to dashboard Cite

Clinical manifestation of Brugada syndrome (BrS) mainly results from polymorphic ventricular arrhythmias and includes sudden cardiac arrest (SCA). The Brugada sign, besides being present in true BrS, may result from different causes. Moreover, electrocardiogram findings in some clinical situations may resemble the BrS electrocardiographic pattern. Thus, differential diagnosis is crucial in the proper management of patients suspected of having BrS. Lifestyle modifications and close follow-up with or without pharmacologic treatment and/or implantable cardioverter-defibrillator placement constitute the most common approach to managing BrS patients. However, the role of ablation in BrS treatment is increasing. Due to diagnostic and therapeutic difficulties, the management of BrS is often challenging. This review provides new concepts and algorithms in the diagnostics and treatment of patients suspected of having BrS. JRCD 2017; 3 (5): 151-160

show abstract

“…74 Hydroquinidine, a class IA antiarrhythmic drug, inhibits Ito to a greater extent in the epicardium than in the endocardium, and has proven efficacy and safety in a longterm follow-up study. 75 Cilostazol, a phosphodiesterase III inhibitor, normalizes the ST-segment, most likely by augmenting ICa as well as by reducing Ito secondary to an increase in cAMP and heart rate. 76 Finally, combined use of a Chinese herb extract that inhibits Ito and hydroquinidine has been hypothesized.…”

Section: Experimental Therapeutic Options and Future Perspectivesmentioning

confidence: 99%

The Brugada Syndrome　― From Gene to Therapy ―

Curcio

Santarpia

Indolfi

2017

Circ J

View full text Add to dashboard Cite

It is almost a quarter of century that a pioneering work of 2 researchers named Brugada brought the entire scientific community to understanding the molecular, clinical, and electrophysiological aspects of a distinctive syndrome. It affects mainly young adults with syncope and/or sudden cardiac death caused by polymorphic ventricular tachycardia or ventricular fibrillation in the absence of any sign of cardiac degeneration or alteration. Although the involvement of the epicardial layer of the right ventricular outflow tract, and the requirement of pharmacologic challenge for unveiling concealed forms, have been fully characterized, many areas of uncertainties remain to be elucidated, such as the unpredictable usefulness of programmed ventricular stimulation, the role of radiofrequency catheter ablation for reducing ST-segment elevation, and the value of risk stratification in patients diagnosed with upper displacement of right precordial leads. How much Brugada syndrome is an intense field of research is witnessed by 4 different consensus committees that took place in a relatively short period of time considering the recent discovery of this intricate arrhythmogenic disease. The main focus of this review is to describe the milestones in Brugada syndrome from its first phenotypic and genotypic appraisals to recent achievements in electrical therapies proposed for the management of this fascinating rhythm disturbance that, despite new diagnostic and therapeutic learnings, still predisposes to sudden cardiac death.

show abstract

Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine

Abstract: Our long-term follow-up results emphasize that the rate of arrhythmic events among asymptomatic Brugada patients with inducible VF remains low over time. Our results also suggest that residual inducibility under HQ is of limited value to predict events during follow-up.

Cited by 38 publications

References 24 publications

J-wave syndromes: Brugada and early repolarization syndromes

J-wave syndromes: Brugada and early repolarization syndromes

Brugada syndrome: new concepts and algorithms in management (RCD code: V 1A.1)

The Brugada Syndrome　― From Gene to Therapy ―

Contact Info

Product

Resources

About

Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine

Abstract: Our long-term follow-up results emphasize that the rate of arrhythmic events among asymptomatic Brugada patients with inducible VF remains low over time. Our results also suggest that residual inducibility under HQ is of limited value to predict events during follow-up.

Cited by 38 publications

References 24 publications

J-wave syndromes: Brugada and early repolarization syndromes

J-wave syndromes: Brugada and early repolarization syndromes

Brugada syndrome: new concepts and algorithms in management (RCD code: V 1A.1)

The Brugada Syndrome ― From Gene to Therapy ―

Contact Info

Product

Resources

About

The Brugada Syndrome　― From Gene to Therapy ―